

May 15, 2012

ONO PHARMACEUTICAL CO., LTD.

Corporate Communications

Phone: +81-6-6263-5670

**Ono Enters into Drug Discovery Collaboration
with Scil Proteins for Affilin[®] Therapeutics**

Ono Pharmaceutical Co., Ltd. (Osaka, Japan) announced today that Ono and Scil Proteins GmbH (Halle, Germany) signed a collaboration agreement for joint discovery and development of new protein therapeutics. Under the terms of the agreement, Ono will pay to Scil Proteins research funding, and make milestone payments for research, development and commercialization, and royalty payments based on sales.

Scil Proteins will identify unique proteins that bind certain target molecule(s) provided by Ono taking advantage of its proprietary Affilin[®] drug discovery platform. Ono will further evaluate biological activities and safety profiles of selected proteins and discover new protein-based drug candidates. Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical product containing a protein developed through this collaboration.

“This collaboration with Ono is an important commercial milestone for Scil Proteins, which further affirms the technical and scientific concepts behind our Affilin[®] platform”, commented Henning Afflerbach, Scil Proteins’ CBO. “We are pleased to have successfully implemented our fully integrated offering of providing proprietary, fully patent-protected compounds in combination with production process development and GMP manufacturing into a cutting-edge collaborative research with a leading pharmaceutical company. Ono established outstanding scientific and developmental expertise.”

Kazuhito Kawabata, Ph.D., Member of the Board of Directors, Executive Officer and Executive Director, Discovery and Research of Ono said: “We strongly believe that Scil Proteins is the partner of choice to identify proteins binding the target molecules we chose. We are pleased to be working together and look forward to creating innovative drugs for unmet medical needs.”

– Ends –

About Scil Proteins

Scil Proteins is a biopharmaceutical company discovering and developing Affilin[®] molecules and working with industry partners in the development and manufacture of protein therapeutics and diagnostics. Scil Proteins has built a pipeline of Affilin[®] therapeutics targeting cancer. In addition, the Company has a longstanding expertise in protein production and process development and, therefore, offers GMP contract biomanufacturing to its clients in the biotech and pharma industries.

With state-of-the-art equipment and a particular expertise in refolding proteins, the Company has an excellent track record in supplying top level support for its partners. Scil Proteins has supported a number of different companies such as Roche, Actavis and Lundbeck in process development and manufacturing of recombinant protein drugs. Scil Proteins is a well-established private company located in Halle, Germany. To learn more about Scil Proteins, please visit www.scilproteins.com.

About Affilin[®]

Scil Proteins' proprietary Affilin[®] platform allows the generation of innovative biopharmaceuticals. Affilin[®] molecules are ubiquitin-based proteins that bind targets with high affinity, specificity, heat stability, and little immunogenicity, which are highly important features as therapeutics.